Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

The Moderna Covid-19 vaccine. Photo: Steve Parsons/pool/AFP via Getty Images

Moderna's COVID-19 vaccine is more than 90% effective against the coronavirus approximately six months after the second dose is administered, according to preliminary data published in the New England Journal of Medicine.

Why it matters: Details about the Moderna vaccine's long-term effectiveness come after the FDA recommended earlier Tuesday that the U.S. pause its use of Johnson & Johnson's coronavirus vaccine, citing six cases of a rare blood clot disorder.

  • The White House quickly put out a statement saying the Biden administration has secured enough Moderna and Pfizer doses for 300 million Americans after the FDA's recommendation.

What they found: Antibody activity lasted six months after the second Moderna dose, per the company's ongoing study.

  • Moderna is also studying immune responses beyond the six-month mark as well as whether booster shots are effective against variants.

What they're saying: “We are looking forward to having the clinical data from our variant-specific booster candidates, as well as clinical data from the Phase 2/3 study of our COVID-19 vaccine in adolescents,” Moderna CEO Stéphane Bancel said in a press release.

Go deeper

Apr 13, 2021 - Health

White House says J&J pause will not have "significant impact" on vaccination plan

Biden at the White Houe on April 6. Photo: Oliver Contreras/Sipa/Bloomberg via Getty Images

The White House said Tuesday that the FDA's recommendation that the U.S. pause use of Johnson & Johnson's COVID-19 vaccine "will not have a significant impact" on the administration's vaccination plans.

Why it matters: The Biden administration says it has secured enough Moderna and Pfizer doses for 300 million Americans. The U.S. will be able to continue administering 3 million vaccine doses a day even without the Johnson & Johnson shot, according to the White House.

Apr 13, 2021 - Health

Moderna says its COVID-19 vaccine has not led to blood clots following J&J reports

Photo: Steve Parsons/Pool/AFP via Getty Images

Moderna released a statement Tuesday reassuring people of the safety of its coronavirus vaccine hours after the FDA recommended pausing the administration Johnson & Johnson (J&J) vaccines due to reported cases of "extremely rare" blood clots.

What they're saying: After over 64.5 million doses administered globally, a comprehensive assessment using data through March 22 "does not suggest an association with" blood clots in the brain or veins, Moderna said.

Updated Apr 13, 2021 - Health

FDA expects J&J vaccine pause to last "a matter of days"

Photo: Michael Ciaglo/Getty Images

The U.S. FDA on Tuesday recommended an immediate halt of the use of Johnson & Johnson's COVID-19 vaccine, citing cases of a rare blood clot disorder that six women developed within two weeks of receiving the shot.

The latest: Acting FDA Commissioner Janet Woodcock said at a briefing that she expects the pause to only last "a matter of days," as health officials investigate the data surrounding the "extremely rare" blood clots.